IRadimed Corp
NASDAQ:IRMD
IRadimed Corp
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices. The company is headquartered in Winter Springs, Florida and currently employs 110 full-time employees. The company went IPO on 2014-07-16. Its MRidium 3860+ MRI Compatible IV infusion pump system provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to deliver anesthesia safely and predictably and other IV medications or fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The firm sells its products primarily to hospitals and acute care facilities, both in the United States and internationally.
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices. The company is headquartered in Winter Springs, Florida and currently employs 110 full-time employees. The company went IPO on 2014-07-16. Its MRidium 3860+ MRI Compatible IV infusion pump system provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to deliver anesthesia safely and predictably and other IV medications or fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The firm sells its products primarily to hospitals and acute care facilities, both in the United States and internationally.
Record Revenue: Iradimed reported its 18th consecutive quarter of record revenue, reaching $22.7 million in Q4 2025, up 17% year-over-year and above previous guidance.
Full-Year Growth: 2025 full-year revenue hit $83.8 million, representing 14% growth, with robust contributions from all product lines.
Earnings Strength: Quarterly diluted EPS was $0.50, up 25% from last year, and annual diluted EPS reached $1.75, up 17%.
Product Launch Momentum: Strong initial feedback for the new 3870 MR IV pump, with bookings expected to ramp significantly in the second half of 2026.
Margin Outlook: Gross margin remained solid at 75% for Q4 and 77% for the full year, with potential for slight improvement later in 2026 as new pump volumes increase.
Guidance: Management reaffirmed confidence in reaching a $100 million-plus revenue run rate during 2026.
